| A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB) (NCT07640984) | JCR Pharmaceuticals Co., Ltd. | 2026-06-18 |
| A Long-Term Observational Study of Patients With Fucosidosis (NCT07615400) | JCR Pharmaceuticals Co., Ltd. | 2026-03-25 |
| An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB (NCT06488924) | JCR Pharmaceuticals Co., Ltd. | 2024-11-05 |
| Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA (NCT06095388) | JCR Pharmaceuticals Co., Ltd. | 2023-10-04 |
| A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT) (NCT04573023) | JCR Pharmaceuticals Co., Ltd. | 2022-02-14 |
| An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I) (NCT04453085) | JCR Pharmaceuticals Co., Ltd. | 2021-10-28 |
| A Study of JR-171 in Patients With Mucopolysaccharidosis I (NCT04227600) | JCR Pharmaceuticals Co., Ltd. | 2020-09-01 |
| An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II (NCT04348136) | JCR Pharmaceuticals Co., Ltd. | 2019-09-01 |
| An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II (NCT03708965) | JCR Pharmaceuticals Co., Ltd. | 2019-01-01 |
| A Study of JR-141 in Patients With Mucopolysaccharidosis II (NCT03568175) | JCR Pharmaceuticals Co., Ltd. | 2018-08-01 |